Peptides for wound healing — from chronic ulcers to surgical recovery

Conventional wound care has made meaningful advances in the past two decades — negative pressure wound therapy, bioengineered skin substitutes, advanced dressings that maintain moisture, growth factor formulations — but the gap between "the wound should be healing faster" and "here's something additional that might help" remains real for many patients. It is in this context that the peptide research landscape for wound healing has developed, and it is a landscape with some genuine depth — because wound healing is one of the areas where peptide biology has the longest research history and, in at least one case, direct regulatory precedent.

Wound healing proceeds through four overlapping biological phases, and understanding them provides the map for understanding where different peptides have been researched to act. Hemostasis — clot formation to stop bleeding — occurs within minutes of injury. Inflammation follows, with immune cells arriving to clean debris and defend against infection; this phase typically peaks at 48 to 72 hours. Proliferation is the repair phase, where fibroblasts synthesize new collagen, keratinocytes migrate to resurface the wound, and new blood vessels grow in to supply the rebuilding tissue. Remodeling then occurs over weeks to months as the initial repair matrix is reorganized into mature scar tissue with greater tensile strength. Conditions that impair wound healing generally do so by disrupting one or more of these phases: diabetes impairs all of them through microvascular insufficiency, impaired immune cell function, and reduced growth factor signaling; poor vascular supply starves the wound of oxygen and nutrients; immunosuppression (from disease or medication) leaves the wound vulnerable to infection and impairs the inflammatory phase that is, paradoxically, essential for triggering repair; malnutrition deprives the tissue of the amino acids and micronutrients needed for collagen synthesis; and aging reduces fibroblast proliferative capacity, growth factor expression, and tissue repair velocity at every phase.

GHK-Cu — the copper-binding tripeptide glycine-histidine-lysine — is the original wound healing peptide in the sense that it was discovered specifically in the context of wound repair research. Biochemist Loren Pickart first identified GHK as a plasma factor that promoted liver cell regeneration in the 1970s, and subsequent research showed that GHK released from damaged tissue sites acts as a wound signal — recruiting repair cells, stimulating collagen synthesis, promoting angiogenesis, and modulating inflammation. The copper-bound form, GHK-Cu, has demonstrated in vitro and in vivo effects including increased synthesis of collagen, elastin, and glycosaminoglycans, enhanced fibroblast migration and proliferation, promotion of angiogenesis through vascular endothelial growth factor upregulation, and anti-inflammatory activity. The regulatory history is notable: the Iamin gel formulation of GHK-Cu received FDA clearance as a medical device for wound care and skin management — one of the few cases where a peptide compound has cleared a regulatory pathway directly related to tissue repair. Topical GHK-Cu is widely used in wound care and cosmetic dermatology contexts. Systemic administration via subcutaneous injection is not FDA-approved and exists in research and compounding contexts; the evidence for systemic wound healing effects is far less developed than the topical literature.

BPC-157 is the peptide with the broadest preclinical tissue repair literature in this space. Studies in rodent models have examined BPC-157's effects on wound healing across tissue types — skin wounds, muscle tears, tendon injuries, ligament injuries, bone fractures, and gut mucosal damage. The consistent preclinical pattern is accelerated healing: reduced time to wound closure, improved tensile strength of repaired tissue, enhanced angiogenesis, and reduced inflammatory markers at injury sites. The proposed mechanisms are multiple — BPC-157 appears to upregulate growth hormone receptor expression, stimulate nitric oxide synthesis, and modulate the FAK-paxillin pathway involved in cell migration. It may also interact with the dopaminergic and serotonergic systems in ways that influence tissue healing indirectly. The preclinical breadth is genuinely impressive. The human clinical evidence is essentially absent — there are no published large randomized controlled trials of BPC-157 in wound healing. It is not FDA-approved. The confidence level for its wound healing effects in humans must remain at "preclinical animal model data with mechanistic rationale for human relevance" — which is a meaningful distinction from clinical evidence.

TB-500 is the synthetic peptide fragment of Thymosin Beta-4 that has been most commonly used in research and compounding contexts. Thymosin Beta-4 is an endogenous peptide with multiple roles including regulation of actin polymerization, cell migration, and tissue repair. In wound healing, Thymosin Beta-4 has been researched for its ability to stimulate keratinocyte and endothelial cell migration — two cell movements that are essential for wound resurfacing and angiogenesis respectively. Clinical research on Thymosin Beta-4 in corneal wounds demonstrated accelerated healing in a controlled trial, which represents one of the more rigorous human datasets in this space. Research has also explored it in dermal wound contexts, cardiac tissue after ischemia, and tendon repair. TB-500 itself — the actin-binding fragment — is not the same as full Thymosin Beta-4 and its regulatory status is distinct; it is not FDA-approved and is primarily used in research contexts. The human wound evidence for Thymosin Beta-4 is more developed than for most peptides in this landscape, though it is limited to specific tissue types and small trials.

LL-37 is an antimicrobial peptide — a member of the cathelicidin family — that sits at the intersection of infection defense and wound healing. The wound environment presents two competing needs: clearing infection and promoting repair, and the inflammatory processes that address infection can also impair healing if they persist too long. LL-37 is produced naturally by neutrophils and epithelial cells at wound sites, where it provides direct antimicrobial activity against bacteria, fungi, and viruses while also stimulating angiogenesis and keratinocyte migration. Research has explored LL-37 as a therapeutic agent for chronic wounds, particularly diabetic ulcers where bacterial biofilm is a major contributor to non-healing. Phase 2 trial data in venous leg ulcers showed improved healing in the LL-37 treatment group compared to placebo. This is among the more compelling human datasets in the wound peptide space. LL-37 is not FDA-approved for clinical wound care use and development continues.

ARA-290 enters the wound healing picture through the diabetic wound angle. Diabetic foot ulcers are driven in significant part by peripheral microvascular insufficiency and small fiber nerve dysfunction, which impairs both the blood supply to healing tissue and the neurogenic signals that contribute to wound repair. ARA-290 — the erythropoietin-derived tissue-protective peptide — has demonstrated improvements in small fiber neuropathy and microvascular inflammation in diabetic peripheral neuropathy research. The logic connecting ARA-290 to diabetic wound healing is mechanistically sound: if the microvascular environment that supplies diabetic wounds is improved, healing conditions improve. But direct clinical trial data on ARA-290 for wound healing specifically is limited. The compound is not FDA-approved and the wound healing application is inferred from its neuropathy research more than tested directly in wound-specific trials.

KPV is a tripeptide derived from the C-terminal sequence of alpha-MSH — lysine-proline-valine — with potent anti-inflammatory properties mediated through the melanocortin receptor system. Research has explored KPV in inflammatory wound models, including intestinal inflammation (where it has shown effects in IBD models) and skin wound models where excessive inflammation impairs healing. The rationale for using an anti-inflammatory peptide in wound care addresses the problem of wounds stuck in the inflammatory phase — where the immune response that was initially necessary for debridement and defense has become chronic and is now preventing the transition to proliferation and repair. KPV research in this context is primarily preclinical; it is not FDA-approved and has not been validated in large clinical wound care trials.

The diabetic foot ulcer context deserves specific attention because it represents both the greatest unmet need in wound care and the area where peptide-related research has generated the most concentrated interest. Diabetic foot ulcers account for the majority of non-traumatic lower extremity amputations in the United States. Standard of care includes debridement, offloading, infection management with appropriate antibiotics, and increasingly bioengineered skin substitute application. Despite this standard of care, a significant proportion of diabetic ulcers do not heal within 12 weeks and enter the chronic non-healing trajectory. The combination of impaired vascularity, neuropathy, impaired immune response, biofilm formation, and impaired growth factor signaling creates a wound environment that is biologically resistant to healing. Multiple peptides have been researched for this specific context because the need is so great and the conventional toolkit insufficient.

Standard wound care principles remain foundational regardless of any adjunctive peptide approach. Debridement — removing necrotic tissue, biofilm, and cellular debris — is the essential first step without which no repair process can proceed effectively. Offloading pressure from foot wounds is perhaps the single most important intervention for diabetic foot ulcers; total contact casting is the gold standard. Infection control — identifying and treating bacterial biofilm and systemic infection — is prerequisite. Nutritional support, particularly adequate protein intake, is essential for collagen synthesis. Vascular evaluation and, where appropriate, revascularization is necessary when impaired blood flow is limiting healing. These fundamentals carry clinical evidence; peptide adjuncts are research additions to this framework, not replacements for it.

Post-surgical recovery is a separate context where wound healing biology is relevant — the question of whether interventions might accelerate incision healing, reduce scar formation, or improve recovery of the deeper tissue layers repaired during surgery. This is an area where the peptide research rationale has attracted attention, particularly in the functional medicine and optimization space, but where clinical trial data guiding specific protocols is limited.

For anyone with a wound that is not progressing as expected — particularly in the context of diabetes, vascular disease, or post-surgical recovery — wound care specialist evaluation is the appropriate starting point. That evaluation can identify the specific barrier to healing, whether vascular, infectious, nutritional, or mechanical, and guide a comprehensive management approach. Conversations about research-stage peptides as potential adjuncts belong within that clinical framework, with a prescribing provider who understands both the evidence and your individual wound biology.